[go: up one dir, main page]

GB202306826D0 - Therapy - Google Patents

Therapy

Info

Publication number
GB202306826D0
GB202306826D0 GBGB2306826.5A GB202306826A GB202306826D0 GB 202306826 D0 GB202306826 D0 GB 202306826D0 GB 202306826 A GB202306826 A GB 202306826A GB 202306826 D0 GB202306826 D0 GB 202306826D0
Authority
GB
United Kingdom
Prior art keywords
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2306826.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adjutec Pharma AS
Original Assignee
Adjutec Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adjutec Pharma AS filed Critical Adjutec Pharma AS
Priority to GBGB2306826.5A priority Critical patent/GB202306826D0/en
Publication of GB202306826D0 publication Critical patent/GB202306826D0/en
Priority to PCT/EP2024/062881 priority patent/WO2024231522A1/en
Priority to CN202480041358.0A priority patent/CN121398815A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB2306826.5A 2023-05-09 2023-05-09 Therapy Ceased GB202306826D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB2306826.5A GB202306826D0 (en) 2023-05-09 2023-05-09 Therapy
PCT/EP2024/062881 WO2024231522A1 (en) 2023-05-09 2024-05-09 Therapy
CN202480041358.0A CN121398815A (en) 2023-05-09 2024-05-09 therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2306826.5A GB202306826D0 (en) 2023-05-09 2023-05-09 Therapy

Publications (1)

Publication Number Publication Date
GB202306826D0 true GB202306826D0 (en) 2023-06-21

Family

ID=86763224

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2306826.5A Ceased GB202306826D0 (en) 2023-05-09 2023-05-09 Therapy

Country Status (3)

Country Link
CN (1) CN121398815A (en)
GB (1) GB202306826D0 (en)
WO (1) WO2024231522A1 (en)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599557A (en) 1992-04-30 1997-02-04 Schering Corporation Stable hydrated cephalosporin dry powder for oral suspension formulation
AR004014A1 (en) 1995-10-13 1998-09-30 Meiji Seika Kaisha AN ANTIBACTERIAL COMPOSITION OF CEFDITOREN PIVOXILO FOR ORAL ADMINISTRATION AND METHOD TO OBTAIN SUCH COMPOSITION
ES2251373T3 (en) 1999-04-30 2006-05-01 Excel Corporation METHOD OF TREATMENT OF AN ANIMAL CHANNEL AND APPLIANCE TO PRODUCE ELECTRICAL STIMULATION.
AU2004211931A1 (en) 2003-02-06 2004-08-26 Bioresponse, L.L.C. The combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions
WO2006043153A2 (en) 2004-10-20 2006-04-27 Michel Xilinas Use of zinc and copper chelators for the treatment of viral diseases
AU2009206119C1 (en) 2008-01-18 2016-05-26 Merck Sharp & Dohme Llc Beta-lactamase inhibitors
WO2009140215A2 (en) 2008-05-11 2009-11-19 Geraghty, Erin Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds
ES2524792T3 (en) 2008-05-30 2014-12-12 University Of Cincinnati Use of zinc chelators comprising dtpa to inhibit the formation of biofilms
US9139597B2 (en) 2009-05-25 2015-09-22 Sandoz Ag Method for the production of ceftobiprole medocaril
FR2951171A1 (en) 2009-10-09 2011-04-15 Novexel NOVEL SODIUM SALT OF A CRYSTALLIZED ENANTIOMER AZABICYCLIC COMPOUND AND NOVEL POLYMORPHIC AND PSEUDOPOLYMORPHIC FORMS AND THEIR PREPARATION
EP2504025A4 (en) 2009-11-23 2013-05-01 Stephen F Olmstead COMPOSITIONS AND METHODS COMPRISING SERRATIA PEPTIDASE FOR THE INHIBITION AND TREATMENT OF BIOFILMS RELATED TO CERTAIN PATHOLOGIES
AU2012303691B2 (en) 2011-08-27 2014-06-19 Wockhardt Limited 1,6- diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
WO2013038330A1 (en) 2011-09-13 2013-03-21 Wockhardt Limited Nitrogen containing compounds and their use
UY35103A (en) 2012-10-29 2014-05-30 Glaxo Group Ltd 2-REPLACED CEFEM COMPOUNDS
EP2953626A1 (en) 2013-02-06 2015-12-16 Astrazeneca AB Combination therapy for the treatment of nosocomial pneumonia
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
GB201317619D0 (en) 2013-10-04 2013-11-20 Uni I Oslo Compounds
EP3189841B1 (en) 2014-09-04 2023-11-22 Shionogi & Co., Ltd. Pharmaceutical preparation comprising cephalosporin having catechol groups
MX2017013433A (en) 2016-03-31 2018-01-30 Wockhardt Ltd Antibacterial compositions.
GB201613946D0 (en) 2016-08-15 2016-09-28 Univ Oslo Compounds
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
DK3833665T3 (en) 2018-08-09 2023-10-09 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases

Also Published As

Publication number Publication date
CN121398815A (en) 2026-01-23
WO2024231522A1 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
CA221425S (en) Therapy eye-mask
GB202113079D0 (en) New therapy
IL319599A (en) Combination therapy
GB202103164D0 (en) Therapy
GB202002639D0 (en) Therapy
IL318268A (en) Combination therapy
GB202111035D0 (en) Therapy
GB202108303D0 (en) Therapy
GB202315877D0 (en) Therapy
GB202306835D0 (en) Therapy
GB202306833D0 (en) Therapy
GB202306826D0 (en) Therapy
GB202303026D0 (en) Therapy
GB202219335D0 (en) Therapy
GB202218595D0 (en) Therapy
GB202215997D0 (en) Therapy
GB202214514D0 (en) Therapy
IL325619A (en) Combination therapy
GB202318311D0 (en) Combination therapy
GB202317996D0 (en) Combination therapy
GB202316168D0 (en) Combination therapy
GB202315149D0 (en) Combination therapy
GB202314243D0 (en) Combination therapy
GB202314157D0 (en) Combination therapy
GB202306663D0 (en) Combination therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)